HCA HCA Healthcare
Health Care · S&P 500
Next earnings: Tue 26 Jan 2027 · estimated
What 27 analyst firms say about HCA Healthcare: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
24 rated views · 27 analyst/firm records · 27 firms
Radar score
- S&P 500 · Top Picks · 6MNot scored · Average target is not above the current price
- S&P 500 · Safest consensus · 6MNot scored · Average target is not above the current price
Recent analyst activity · last 90 days
Our tracked history has 23 reports on HCA from 18 analyst firms in the last 90 days (27 firms in the past year).
Comparing each firm's latest target with its previous one: 10 raised their price target, 1 lowered it, 3 left it unchanged and 1 has its first observed target in the past year.
No firm's latest available rating differs from its previous one.
Latest observed target change: Truist Securities raised its target from $495.00 (set 27 Jul 2026) to $510.00 on 3 Nov 2026.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Argus | David A Toung | Buy | 10 Aug 2026 | 500.00 USD |
| Baird | Michael Ha | Hold | 28 Oct 2026 | 409.00 USD |
| Bank of America Securities | Kevin Fischbeck | Hold | 28 Oct 2026 | 500.00 USD |
| Barclays | Andrew Mok | Hold | 29 Oct 2026 | 401.00 USD |
| Bernstein | Lance A Wilkes | Hold | 28 Oct 2026 | 471.00 USD |
| BMO Capital Markets | Sean Dodge | Buy | 22 Sep 2026 | 495.00 USD |
| Cantor Fitzgerald | Sarah James | Buy | 2 Oct 2026 | Conflicting reports · excluded |
| Deutsche Bank | Unnamed analyst | — | 27 Jul 2026 | 476.00 USD |
| Goldman Sachs | Scott Fidel | Buy | 28 Jul 2026 | 485.00 USD |
| Guggenheim | Jason Cassorla | Hold | 1 Jun 2026 | — |
| Jefferies | Brian G Tanquilut | Buy | 28 Oct 2026 | 525.00 USD |
| JPMorgan | Benjamin Rossi | Hold | 20 Aug 2026 | 425.00 USD |
| KeyBanc Capital Markets | Matthew Gillmor | Buy | 28 Oct 2026 | 490.00 USD |
| Leerink Partners | Whit Mayo | Buy | 18 Sep 2026 | 492.00 USD |
| Mizuho | Ann Hynes | ConflictConflicting reports · excluded | 28 Oct 2026 | 495.00 USD |
| Morgan Stanley | Craig Hettenbach | Sell | 27 Jul 2026 | 380.00 USD |
| Oppenheimer | Michael Wiederhorn | Buy | 27 Jul 2026 | 485.00 USD |
| Raymond James | Andrew Cooper | Hold | 27 Oct 2026 | — |
| RBC Capital Markets | Ben Hendrix | Buy | 30 Oct 2026 | 521.00 USD |
| Stephens | Raj Kumar | Buy | 9 Jul 2026 | 480.00 USD |
| TD Cowen | Ryan Langston | Buy | 28 Oct 2026 | 486.00 USD |
| Truist | David MacDonald | Buy | 27 Jul 2026 | 495.00 USD |
| UBS | A.J. Rice | Buy | 27 Jul 2026 | 579.00 USD |
| Weiss Ratings | Unnamed analyst | — | 8 Oct 2026 | — |
| Wells Fargo | Stephen Baxter | Hold | 3 Aug 2026 | 381.00 USD |
| Wolfe Research | Justin Lake | Hold | 1 Jul 2026 | — |
| Data feed RESEARCH | Research Team | Hold | 9 May 2026 | 484.00 USD |
Partial coverage · checked 6 Nov (6 Nov 2026, 03:56 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.